Clinical Trials Logo

Immunotherapy clinical trials

View clinical trials related to Immunotherapy.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05740800 Active, not recruiting - Immunotherapy Clinical Trials

Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding Immunotherapy: A Qualitative and Quantitative Mixed Methods Study

Start date: October 18, 2019
Phase:
Study type: Observational

Immunotherapy is currently a crucial cancer treatment option. Despite the development of new cancer treatment, patients and their family caregivers still experience complex psychological feelings and challenges about the effectiveness of immunotherapy, financial burden, and treatment related side effects which reflect the problems related to decision-making and the supportive care needs.

NCT ID: NCT04670445 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

UPLIFT
Start date: January 23, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer. The intervention is an educational video and question prompt list (QPL) to promote communication between patients, caregivers, and the oncology team about the risks and benefits of immunotherapy.

NCT ID: NCT04586088 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.

NCT ID: NCT04552522 Active, not recruiting - Immunotherapy Clinical Trials

Immunological Response After Shrimp Oral Immunotherapy Treatment

Start date: August 28, 2020
Phase: N/A
Study type: Interventional

Oral immunotherapy is effective in desensitized food allergy. Shrimp allergy is increasing in Thailand. So the purpose of our study is to determine level of specific immunoglobulin E antibodies to shrimp, Immunoglobulin G4 and immunoblot analysis in shrimp allergy patients after shrimp oral immunotherapy.

NCT ID: NCT04405622 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Start date: May 30, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT04387500 Active, not recruiting - Clinical trials for Carcinoma, Renal Cell

Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab injection combined with Inlyta in fumarate hydratase-deficient renal cell carcinoma.

NCT ID: NCT04231552 Active, not recruiting - Rectal Cancer Clinical Trials

Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer

Start date: November 10, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in patients with locally advanced resectable rectal cancer.

NCT ID: NCT04169841 Active, not recruiting - Immunotherapy Clinical Trials

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

GUIDE2REPAIR
Start date: February 10, 2020
Phase: Phase 2
Study type: Interventional

The study propose to generate a clinical trial based on precision medicine to evaluate the use of immunotherapy in patients with altered homologous recombination repair genes and without progression after prior targeted therapy.

NCT ID: NCT04156698 Active, not recruiting - Immunotherapy Clinical Trials

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Start date: May 21, 2020
Phase: Phase 2
Study type: Interventional

This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study.

NCT ID: NCT03066986 Active, not recruiting - Immunotherapy Clinical Trials

Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)

Jumpvax
Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the potential use of delta-inulin as an adjuvant to facilitate the desired immune response to Jack Jumper Ant (JJA) venom with a lower dose of venom, thus reducing adverse reactions, venom requirements and costs of treatment. Specifically we aim to compare outcomes of in-hospital JJA sting challenges and JJA venom specific IgE, and IgG4 responses to semi-rush JJA VIT at maintenance doses of 25 and 50 mcg of JJA venom, with and without delta-inulin adjuvant.